• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Curevac N.V. (NQ: CVAC )

    3.340 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 2, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 367,416
    Open 3.340
    Bid (Size) 4.110 (1)
    Ask (Size) 4.130 (16)
    Prev. Close 3.340
    Today's Range 3.340 - 3.340
    52wk Range 2.215 - 10.87
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    GSK and CureVac to Restructure Collaboration into New Licensing Agreement
    Via ACCESSWIRE
    CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities
    Via ACCESSWIRE

    Performance

    YTD
    -20.29%
    -20.29%
    1 Month
    -23.04%
    -23.04%
    3 Month
    +15.97%
    +15.97%
    6 Month
    -20.29%
    -20.29%
    1 Year
    -68.99%
    -68.99%

    More News

    Read More
    CureVac Announces Voting Results of General Meeting
    Via ACCESSWIRE
    Why Quantum Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update
    Via ACCESSWIRE
    First Human Death From Bird Flu Strain Puts Vaccine Stocks Back On The Map
    Via Benzinga
    Why Lands' End Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    Ollie's Bargain Outlet Posts Upbeat Earnings, Joins Verint Systems, Guidewire Software And Other Big Stocks Moving Higher On Wednesday
    Via Benzinga
    CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK
    Via ACCESSWIRE
    Why XP Shares Are Trading Lower By Around 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    Analog Devices Posts Strong Earnings, Joins TJX, Williams-Sonoma And Other Big Stocks Moving Higher On Wednesday
    Via Benzinga
    Despegar.com Posts Strong Sales, Joins Reddit, Robinhood And Other Big Stocks Moving Higher On Friday
    Via Benzinga
    CVAC Stock Earnings: CureVac Misses EPS, Misses Revenue for Q4 2023
    Via InvestorPlace
    3 Stocks to Purge ASAP Before They’re Pulled off Life Support
    Via InvestorPlace
    Elon Musk Breaks Ranks With GOP By Praising Genetic Engineering Tech That Helped Fight COVID-19: 'Digital Medicine With Incredible Potential'
    Via Benzinga
    Spirit Airlines Posts Weak Results, Joins Integra LifeSciences, Bowlero And Other Big Stocks Moving Lower On Monday
    Via Benzinga
    COVID-19 Patent Dispute Sorted: Acuitas Therapeutics and CureVac Reach Settlement In Patent Battle
    Via Benzinga
    Topics Intellectual Property Lawsuit
    Exposures COVID-19 Financial Intellectual Property
    CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update
    Via ACCESSWIRE
    CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK
    Via ACCESSWIRE
    CureVac Appoints Thaminda Ramanayake as New Chief Business Officer
    Via ACCESSWIRE
    CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024
    Via ACCESSWIRE
    CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines
    Via ACCESSWIRE
    Bill Gates Called For A 'Universal Flu Vaccine,' Now The CDC Director Says The Organization Is 'Activated' After Issuing Bird Flu Alert
    Via Benzinga
    CureVac, GS Partner Release Data On Influenza Vaccine Study
    Via Benzinga
    CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
    Via ACCESSWIRE
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.